HIV Vaccine Candidates from Merck and Aventis Used Together Generate Encouraging Anti-HIV Immune Response in Monkeys
Companies to Collaborate on Early Human Testing This Year
31-Mar-2003 -
Lyon, France and Whitehouse Station, NJ, USA - A combination of two anti-HIV-1 vaccine candidates developed by Aventis Pasteur, a subsidiary of Aventis, and Merck and Co., Inc. elicited levels of a cellular immune response against HIV-1 infection in monkeys that were higher than the levels ...
adenovirus
Aventis
clinical trials
+5